Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nassim Rad

Physical Medicine & Rehabilitation Seattle, WA Medical Doctor

NPI 1821385444 CMS profile 1269028

1959 Ne Pacific St, Seattle, WA 98195

Open in the dashboard

General payments

$231,188

166 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nassim Rad of Seattle, WA is reported in the CMS Open Payments database as having received $231,188 across 166 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $74,407 54
2024 General $60,049 32
2023 General $33,147 30
2022 General $29,572 15
2021 General $29,695 20
2020 General $1,566 13
2019 General $2,752 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nassim Rad
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Nassim Rad were reported at $74,407. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Nassim Rad Physical Medicine & Rehabilitation median Middle half National median
2019 $2,752 $133 $45–$390 $163
2020 $1,566 $88 $29–$272 $114
2021 $29,695 $116 $33–$360 $132
2022 $29,572 $123 $40–$378 $149
2023 $33,147 $131 $43–$396 $160
2024 $60,049 $141 $45–$409 $164
2025 $74,407 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $200,244 133 payments
  2. ITF Therapeutics LLC $26,854 13 payments
  3. Mitsubishi Tanabe Pharma Development America, Inc. $1,460 11 payments
  4. Amylyx Pharmaceuticals, Inc. $1,389 2 payments
  5. Genentech USA, Inc. $769 1 payment
  6. Sarepta Therapeutics, Inc. $179 2 payments
  7. Genentech, Inc. $172 2 payments
  8. Catalyst Pharmaceuticals, Inc. $104 1 payment
  9. UCB, Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $139,676 47 payments
  2. Consulting Fee $58,465 25 payments
  3. Honoraria $18,229 8 payments
  4. Travel and Lodging $11,656 35 payments
  5. Food and Beverage $2,735 44 payments
  6. Education $427 7 payments
Products named General payments · program years 2019–2025
  1. SPINRAZA $151,676 91 payments
  2. Skyclarys $40,365 35 payments
  3. Zurzuvae $3,083 1 payment
  4. RELYVRIO $1,389 2 payments
  5. Evrysdi $941 3 payments
  6. AGAMREE $104 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

358

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$4,229,142

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

51.1%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Evrysdi Risdiplam Brand 53 $1,660,408
Skyclarys Omaveloxolone Brand 27 $858,379
Radicava Ors Edaravone Brand 60 $840,941
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 20 $700,632
Relyvrio Sod Phenylbutyrat/Taurursodiol Brand 12 $156,296
Riluzole Generic 24 $8,446
Baclofen Generic 30 $1,830
Gabapentin Generic 49 $803
Pregabalin Generic 14 $489
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 11 $388

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$18,264

Medicare's payments for the services billed

Medicare patients

140

Average age 66

Services billed

318

70 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 54%
Arthritis 38%
Depression 27%
Osteoporosis 20%
Heart failure 18%
Ischemic heart disease 16%
Diabetes 14%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SPINRAZA
  • Biogen, Inc. $48,989
$48,989 — —
Skyclarys
  • Biogen, Inc. $9,248
$9,248 27 —
Evrysdi
  • Genentech USA, Inc. $769
$769 53 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

166 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record